While it is possible that CGRP may have a limited impact in male rodents (Waldecker et al., 2008), monoclonal antibodies targeting CGRP to treat migraine have been shown equally safe and effective in males and females (Paige et al., 2022, Ornello et al., 2021). This evidence concerns the gene CALCA and migraine disorder.